-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4422 Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?

Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Adult, Combination therapy, Clinical Practice (Health Services and Quality), Therapy sequence, Treatment Considerations, Human, Study Population
Monday, December 9, 2024, 6:00 PM-8:00 PM

Ana Marin Niebla, MD PhD1*, Mariana Bastos-Oreiro2*, Amanda Isabel Perez, MD3*, Alba Cabirta Touzón, MD4*, Fatima De la Cruz Vicente, MD5*, Marta Canelo6*, Ana Jiménez Ubieto7*, Sonia González De Villambrosia8*, Ana Muntañola9,10*, Hugo Daniel Luzardo Henríquez11*, Eduardo Rios Herranz, MD12*, Beatriz De La Cruz13*, Raul Cordoba, MD, PhD14, Ana Saus Carreres15*, Alejandro Martín García-Sancho16*, Ana Garcia Noblejas, MD, PhD17*, Carlos Grande18*, Pablo Prieto Martinez, MD19*, Concepción Nicolás20*, Antonio Gutierrez, MD, PhD21*, Jose-Angel Hernandez Rivas, MD, PhD22*, Blanca Sánchez-González23*, Rosalia Alonso Trillo, MD24*, Eva Donato25*, Paola Villafuerte Gutiérrez26*, Daniel García Belmonte27*, Silvia Rocio Verdesoto Cozzarelli28*, Sandra Suarez Ordoñez, MD29*, Emilia Pardal De La Mano30*, Lucia Villalon Blanco31*, Eva Gine, MD32, Juan-Manuel Sancho, MD, PhD33*, Alberto Lopez Garcia, MD34, Alicia Roldán-Pérez35*, Pilar Gómez36*, Victor Navarro Garces, BSc37* and Pau Abrisqueta, MD PhD38

1Hematology Department, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Barcelona, Spain
2Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
3Department of Hematology, ICAMS, Hospital Clínic de Barcelona, Barcelona, Spain., Barcelona, Spain
4Hematology Department, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain
5Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, University Hospital Virgen del Rocío, Seville, Spain
6Hematology Department, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
7Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
8Hematology Department, Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain
9MúTua Terrassa, Terrassa University Hospital, Terrassa, ESP
10Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain
11Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
12Hematology Department, University Hospital Ntra. Sra de Valme, Seville, Spain
13Hematology Department, Hospital Universitario La Paz, Madrid, Spain
14Hematology Department, Health Research Institute IIS-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
15Hematology Department, Hospital Clínico de Valencia, Valencia, Spain
16Hematology Department, Salamanca University Hospital, IBSAL, CIBERONC, Salamanca, Spain
17Hematology Department, Hospital Universitario La Princesa, Madrid, Spain
18Hematology Department, Clínica Universidad de Navarra, Madrid, Spain
19Hematology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain
20Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
21Hematology Department, Son Espases University Hospital, IdISBa, Palma, Spain
22Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain
23Hematology Department, Hospital del Mar, Barcelona, Spain
24Hematology Department, Hospital Universitario de Getafe, Madrid, Spain
25Hematology Department, Hospital Universitario Doctor Peset, Valencia, Spain
26Hematology Department, Hospital Universitario Principe de Asturias, Madrid, Spain
27Hematology Department, Hospital Universitario la Zarzuela, Madrid, Spain
28Hematololgy Department, Hospital de San Juan Despí Moisès Broggi, Barcelona, ESP
29Hematology Department, Complejo Hospitalario de Vigo, Vigo, Spain
30Hematology Department, Hospital Virgen del Puerto, Plasencia, Cáceres, Spain
31Hospital Universitario Fundación Alcorcón, Alcorc N, Madrid, ESP
32Department of Hematology, ICAMS, Hospital Clínic de Barcelona, Barcelona, Spain
33Clinical Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Spain
34Fundacion Jimenez Diaz University Hospital, Madrid, Spain
35Hematology Department, Hospital Universitario Infanta Sofía, Madrid, Spain
36Hospital La Paz, Madrid, Spain
37Statistics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
38Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain

INTRODUCTION:

Consolidation with ASCT after induction immunochemotherapy (ICT) is the standard strategy in MCL to prolong progression-free survival (PFS) in young fit eligible patients since 2005. HiDAC-based ICT further improved these results and, years later, Rituximab Maintenance (RM) prolongued PFS and overall survival (OS) not only in young patients responding to HiDAC+ASCT but also in those older or non-eligible for such intensive approach, challenging the current role of ASCT consolidation in the era of HiDAC and Rituximab Maintenance.

We described the post-induction management of patients with MCL in Spain and its impact on their survival, with special focus on the results of SCT and RM.

PATIENTS AND METHODS:

We retrospectively analyzed the clinical-biologic data, post-induction management and their impact on PFS and OS in the GELTAMO-MCL-2022 study, excluding indolent cases treated or not after observation. Post-induction treatment (PIT) was individually indicated as per clinical practice and physicians’ criteria and included autologous (ASCT) or allogeneic stem cell transplant (allo-SCT) and/or Maintenance with rituximab (RM) alone or with other agent. ICT regimens were grouped as HiDAC (HD-AraC-based) or non-HiDAC. Kaplan-Meier was used to analyze survival and the COX model for HR (CI95%) and p value of factors associated with PFS and OS.

RESULTS:

Out of 1105 patients diagnosed from 2000-2023 in 32 Spanish centers in the GELTAMO-MCL-2022 study, 757 were in Complete or Partial Response (CR, PC) after upfront ICT and were eligible for PIT and for this analysis: 241 (32%) received RM, 150 (20%) SCT, 127 (17%) sequential SCT-RM and 239 (31.6%) received none.

In the total 277 patients receiving SCT (only 6 allo-SCT), ICT was HiDAC in 85% and non-HiDAC in 15% and age was ≤65yrs in 65% vs. >65 in 10%. In 368 RM (23(6%) +BTKi or lenalidomide), ICT was HiDAC in 45% vs. 55% non-HiDAC, age was ≤65 in 47% vs. 50.6% >65 yrs, median time on RM= 24m(2-160).

SCT patients (vs. non-SCT) were younger (M age 57yr [29-78]) vs. 71 yr [34-91]), more frequently men (78% vs. 29%), had died of infection (11% vs. 4%) and toxicity (28% vs. 21%) rather than progression (44% vs. 50%), had lower MIPI (LR-MIPI 39% vs. 23%), showed higher CRR after ICT (90% vs. 81%) and more L-POD (84% vs. 68%).

With mFU= 89 m, mPFS in SCT vs. Non-SCT patients was 73m vs. 45m (HR=0.57, p<.001) and mOS 152m vs. 86m (HR= 0.61, p<.001). However, when analizing survival by PIT groups, SCT showed no benefit on mPFS over RM (HR=0.98, p=.09) and only ASCT-MR had mPFS and mOS advantage (HR=0.37, p<.001 and HR=0.46, p=.002), while receiving no PIT reduced only mPFS (HR=1.62 p<.001). In multivariate analysis, age at diagnosis, morphologic variant and Ki67 were independently associated with shorter PFS and OS (MIPI also with OS) and both RM and SCT consolidation were associated with longer PFS, but only RM retained its independent impact on OS.

We explored the effect of PIT on PFS/OS in specific subgroups: age, type of ICT, CR vs. PR to 1L, Ki67, TP53 and morphology. When analyzing SCT vs. non-SCT, only patients in CR, classic MCL and Ki67≥30% showed PFS and OS advantage with SCT while no survival advantage was observed in TP53 mutated MCL or according to age (>65 or ≤65). When analyzing the different PIT modalities taking RM alone as reference, SCT alone only showed OS benefit in CR after ICT, while ASCT+RM showed better PFS and OS than RM in both classic MCL and patients in CR after ICT. No PFS or OS advantage of ASCT+RM over RM was observed in the remaining subgroups: >65 or ≤65 (even ≤65 receiving HiDAC), Ki67<30%, patients in PR after ICT and blastoid or TP53 mutated MCL.

CONCLUSIONS:

In our cohort, the highest benefit from SCT is seen in patients achieving CR after 1L, classic MCL and Ki67≥30%, with advantage of ASCT+RM vs. RM, while no survival benefit is observed in patients with blastoid or TP53 mutated MCL and older>65, where RM alone is not inferior to ASCT+RM. In PR after ICT, SCT shows only PFS benefit over no-SCT, and neither SCT or ASCT+RM showed PFS or OS advantage vs. RM.

Regarding HiDAC or non-HiDAC, ASCT+MR showed only longer PFS vs. RM, but not OS. In fact, even in younger patients receiving HiDAC, neither SCT nor ASCT+RM were associated with better PFS or OS vs. RM.

These retrospective data should be taken cautiously, but they might suggest that some of the patients currently eligible for intensive treatment might benefit from the omission of ASCT in the era of rituximab maintenance.

Disclosures: Marin Niebla: AstraZeneca: Consultancy, Honoraria; Johnson&Johnson: Consultancy, Honoraria; Eli Lilly: Consultancy, Honoraria; Abbvie: Consultancy. Bastos-Oreiro: Gilead: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Astrazeneca: Honoraria; Sobi: Honoraria; Genmab: Honoraria; Lilly: Honoraria; Incyte: Honoraria; Kite: Honoraria, Research Funding; Janssen: Honoraria; Takeda: Honoraria; BMS: Honoraria; Roche: Honoraria, Research Funding. De la Cruz Vicente: Abbvie, Beigene, Iowa, Eusa Pharma, Janssen, Roche, Takeda: Consultancy, Honoraria. Jiménez Ubieto: Lilly: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sandoz: Speakers Bureau; Regeneron Pharmaceuticals, Inc.: Consultancy; Roche: Consultancy, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Janssen: Speakers Bureau; Novartis: Speakers Bureau; Incyte: Speakers Bureau; Kite-Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Martín García-Sancho: Novartis: Consultancy; Miltenyi Biotec: Consultancy, Honoraria; Lilly: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Genmab: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Takeda: Honoraria; Sobi: Consultancy, Honoraria; Roche: Honoraria, Other: Travel and Accommodation Support; Janssen: Consultancy, Honoraria, Other: Travel and Accommodation Support; Kyowa Kirin: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; IDEOGEN: Consultancy, Honoraria; Gilead/Kite: Consultancy, Honoraria, Other: Travel and Accommodation Support; EUSA Pharma: Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Other: Travel and Accommodation Support; BeiGene: Consultancy, Honoraria. Hernandez Rivas: Janssen, Roche, Abbvie, AstraZeneca, Gilead, BMS-Celgene, Amgen, Takeda, Astra Zeneca, Lilly, Beigene: Other: Scientific Talks; Janssen, Roche, Abbvie, AstraZeneca, Beigene, Lilly, Gilead, BMS-Celgene, Amgen, Takeda, Jazz Pharmaceuticals, Rovi, Incyte, MSD: Membership on an entity's Board of Directors or advisory committees; BMS-Celgene: Research Funding. Gine: Lilly: Honoraria, Research Funding; Astra-Zeneca: Honoraria; Gilead/Kite: Honoraria; Roche: Honoraria; Janssen: Honoraria, Research Funding. Sancho: Sobi: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb-Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Beigene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Myltenyi Biomedicine: Membership on an entity's Board of Directors or advisory committees; Lilly: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead-Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Abrisqueta: Roche: Consultancy, Honoraria, Speakers Bureau; Abbvie: Consultancy, Honoraria, Speakers Bureau; Beigene: Consultancy; Incyte: Honoraria, Speakers Bureau; Astrazeneca: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH